New Study Finds Cases Of Advanced (Metastatic) Prostate Cancer Rise Significantly In Last Decade - Are Changes To PSA Screening Guidelines To Blame?
Sanford Siegel, M.D., President And CEO Of Chesapeake Urology Comments On New Study And Prostate Cancer Screening Guidelines
OWINGS MILLS, Md., July 22, 2016 /PRNewswire-USNewswire/ -- A new study just published in Prostate Cancer and Prostatic Diseases, a journal from Nature, shows that the number of new cases of advanced (metastatic) prostate cancer in the United States has risen by more than 70 percent in the last decade. The study shows a significant increase in advanced prostate cancer diagnoses, especially among the higher risk age group of men ages 55 – 69 years.
The study identified all men diagnosed with prostate cancer in the National Cancer Data Base (2004–2013) at 1,089 different healthcare facilities in the United States. Results showed that the occurrence of metastatic prostate cancer increased from 2007 to 2013 and in 2013 was 72% more than that of 20041.
The authors of the study concluded, "Beginning in 2007, the incidence of metastatic prostate cancer has increased especially among men in the age group thought most likely to benefit from definitive treatment for prostate cancer. These data highlight the continued need for nationwide refinements in prostate cancer screening and treatment."
Dr. Sanford Siegel commented, "With more than 27,000 men who will die from prostate cancer in 2016, the best chance for cure of this disease starts with early diagnosis. The most proven test that we currently have for detecting early forms of prostate cancer is the PSA blood test. While there has been debate on when to begin screening, the fact of the matter is, prostate cancer screening saves lives."
"Chesapeake Urology is committed to caring for men with prostate cancer and also to helping prevent this disease," adds Dr. Siegel. "Since 2006, we've provided over 8,000 men in need with free prostate cancer screening tests through our community outreach efforts. I continue to be passionate about early detection and treatment of this disease for the best outcomes."
Chesapeake Urology's PSA Screening Recommendations:
Chesapeake Urology recommends patients discuss prostate cancer screening with their physician, and if any questions persist, consult a urologist. Men are most at risk for developing significant prostate cancer between ages 55-70. In most cases, we recommend regular screening during this time. Some men may warrant earlier or later screening based on their individual characteristics, and other men may not be good candidates for screening during this time.
Read more: http://prostatecancer.chesapeakeurology.com/media/120270/psa_statement_revised_9-20-13.pdf
MEDIA CONTACT:
Dr. Sanford Siegel is available for media interviews to comment on this new prostate cancer study and on screening guidelines. To schedule an interview with Dr. Siegel, contact Patricia Schnably, VP of Marketing and Communications at Chesapeake Urology - Tel. 443-738-8107 or [email protected].
About Chesapeake Urology
Chesapeake Urology is a fully-integrated urology practice providing a comprehensive array of urologic services to its patients. The Company operates 21 medical offices and 14 AAAHC-certified ambulatory surgery centers in Baltimore, Harford, Howard, Carroll, Montgomery, Prince George's, Charles and Anne Arundel counties and in Baltimore City, and has a staff of more than 500 including 63 physicians. Chesapeake Urology has been named one of the top 100 places to work in healthcare nationally by Modern Healthcare magazine and locally by Baltimore magazine. For information about Chesapeake Urology, please visit ChesapeakeUrology.com or follow us on social media: Facebook: www.Facebook.com/ChesUrology; Twitter: www.Twitter.com/ChesUrology; and YouTube: www.YouTube.com/ChesapeakeUrology.
Contact: Patricia Schnably, Chesapeake Urology
Tel. 443-738-8107
Email: [email protected]
Logo - http://photos.prnewswire.com/prnh/20160212/332730LOGO
SOURCE Chesapeake Urology Associates
Share this article